Owens & Minor, Inc (NYSE:OMI) stands at a crossroads as it receives an average rating of “Hold” from eight analysts recently. The reports indicate that two equities research analysts have recommended selling the stock, whereas three have advised holding the shares in the company. Keeping with the trend, brokers’ assessments on OMI’s average price target for the next 12 months indicate $18.83.
The healthcare solution company is engaged in manufacturing and delivering high-quality products to support care through hospitals and home health facilities via its Products and Healthcare Services and Patient Direct operations. Recently, First Trust Advisors LP purchased 110,033 shares of OMI to increase its holdings by 11.9% in the fourth quarter. The mutual fund entity Mutual of America Capital Management LLC raised its stake in Owens & Minor by a whopping 560.1% during the third quarter.
The hedge funds such as Wolverine Asset Management LLC also reinforced their portfolio of OMI stocks by raising their stake level considerably (59.4%) during the last identified quarter – Q4.
Furthermore, Swiss National Bank picked up minor additional shares (2%) recently while First Eagle Investment Management LLC acquired an extra 5,000 odd shares currently held.
In conclusion, several investors seem confident enough about Owens & Minor’s business outlook that they have been buying more shares recently rather than selling them off even though data suggests a cautious stance based on Hold ratings from most analysts surveyed here in recent times.
Owens & Minor, Inc.
Updated on: 09/06/2023
We did not find social sentiment data for this stock
|Analyst / firm||Rating|
Robert W. Baird
|Robert W. Baird||Buy|
Fluctuating Reviews and Insider Trading: A Look at Owens & Minor Inc’s Recent Performance
Owens & Minor, Inc. continues its trend of earning mixed reviews from various financial institutions and researchers. Credit Suisse Group recently decreased their price target on OMI from $20.00 to $17.00 and set a rating of “neutral” on March 7th, which was followed by Citigroup lowering their price objective from $20.00 to $17.00 with a “neutral” rating on March 8th. However, Robert W. Baird later lifted their price objective in May from $18.00 to $21.00, while StockNews.com began coverage with a “hold” rating on May 18th, and UBS Group upped their target price on Owens & Minor from $22.00 to $24.00 in the same month.
In the latest news regarding insider trading at Owens & Minor, Michael Wayne Lowry sold 10,000 shares for a total transaction of over $211 thousand on June 6th at an average selling price of $21.11 per share, while Senior Vice President (SVP) Jonathan A. Leon sold 6,000 shares worth about $81 thousand on March 22nd and SVP Michael Wayne Lowry sold another 10,000 shares for over $211 thousand in early June as well.
Despite these fluctuations within the market and insider trading activities by company executives alike, Owens & Minor Inc remains steadfastly committed to healthcare solutions that support care through hospitals all the way into private residences via product manufacturing and delivery services alongside perioperative services within its Patient Direct segment and its Products and Healthcare Services business that provides outsourced logistics value-added service operations as well as the manufacture and global sourcing of medical surgical products through kitting operations.
At present time OMI trades at around $21 per share with a market capitalization of approximately USD1.63 billion alongside very low trailing P/E multiples relative to similarly-categorized peers, and analysts have an expected EPS value of USD1.36 for the current fiscal year.